La Jolla Pharmaceutical Co Sample Contracts

RECITALS
Securities Purchase Agreement • October 7th, 2005 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware
AutoNDA by SimpleDocs
3,400,000 Shares La Jolla Pharmaceutical Company UNDERWRITING AGREEMENT
Underwriting Agreement • March 19th, 2018 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • New York
AND
Rights Agreement • December 4th, 1998 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware
BACKGROUND
Rights Agreement • January 26th, 2001 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware
RECITALS
Fourth Amendment • August 6th, 2004 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances)
1 2 ARTICLE I DEFINITIONS
License and Supply Agreement • March 31st, 1997 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
LEASE by and between BMR-AXIOM LP, a Delaware limited partnership and LA JOLLA PHARMACEUTICAL COMPANY, a California corporation
Lease • February 23rd, 2017 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances)
FORM OF REGISTRATION RIGHTS AGREEMENT
Form of Registration Rights Agreement • November 10th, 2003 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
RECITALS
La Jolla Pharmaceutical Co • August 6th, 2004 • Biological products, (no disgnostic substances)
FORM OF STOCK PURCHASE AGREEMENT
Form of Stock Purchase Agreement • November 10th, 2003 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California
INDEMNIFICATION AGREEMENT
Indemnification Agreement • November 2nd, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

This Indemnification Agreement (this “Agreement”) is made as of this day of November, 2021 by and between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”) and (“Indemnitee”).

COMMON STOCK
La Jolla Pharmaceutical Co • March 30th, 2007 • Biological products, (no disgnostic substances) • New York
AutoNDA by SimpleDocs
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreement • March 1st, 2006 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California

This Amended and Restated Employment Agreement (this “Agreement”) is effective as of February 23, 2006 (the “Effective Date”), and is entered into by and between Theodora Reilly (“Employee”) and La Jolla Pharmaceutical Company (the “Company”).

12,250,000 Shares of Common Stock La Jolla Pharmaceutical Company Common Stock Underwriting Agreement
La Jolla Pharmaceutical Co • January 28th, 2005 • Biological products, (no disgnostic substances) • California
LA JOLLA PHARMACEUTICAL COMPANY RESTRICTED STOCK AGREEMENT
Company Restricted Stock Agreement • December 20th, 2013 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances)

This Restricted Stock Agreement (the “Agreement”) is made as of April 29, 2013 (the “Effective Date”) by and between La Jolla Pharmaceutical Company, a California corporation (the “Company”), and James Rolke (“Recipient”).

LA JOLLA PHARMACEUTICAL COMPANY and AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC as Rights Agent Amended and Restated Rights Agreement Dated as of December 2, 2008
Rights Agreement • December 4th, 2008 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

This Amended and Restated Rights Agreement (the “Agreement”), dated as of December 2, 2008, between La Jolla Pharmaceutical Company, a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company (the “Rights Agent”).

AGREEMENT AND PLAN OF MERGER among: LA JOLLA PHARMACEUTICAL COMPANY, a California corporation; TTP MERGER SUB, INC., a Delaware corporation; and TETRAPHASE PHARMACEUTICALS, INC., a Delaware corporation Dated as of June 24, 2020
Agreement and Plan of Merger • June 24th, 2020 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

The corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon the stockholders herein are granted subject to this reservation.

SUPPORT AGREEMENT
Support Agreement • July 12th, 2022 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

This SUPPORT AGREEMENT (this “Agreement”), dated as of July 10, 2022, is entered into by and among INNOVIVA, INC., a Delaware corporation (“Parent”), INNOVIVA ACQUISITION SUB, INC., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”), and each of the stockholders of LA JOLLA PHARMACEUTICAL COMPANY set forth on Schedule A hereto (each, a “Stockholder”). Capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

AGREEMENT AND PLAN OF MERGER among: INNOVIVA, INC., a Delaware corporation INNOVIVA ACQUISITION SUB, INC., a Delaware corporation; and LA JOLLA PHARMACEUTICAL COMPANY, a Delaware corporation Dated as of July 10, 2022
Agreement and Plan of Merger • July 12th, 2022 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of July 10, 2022, by and among INNOVIVA, INC., a Delaware corporation (“Parent”); INNOVIVA ACQUISITION SUB, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”); and LA JOLLA PHARMACEUTICAL COMPANY, a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.

FORM OF EXCHANGE AGREEMENT
Form of Exchange Agreement • June 24th, 2020 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

This EXCHANGE AGREEMENT (this “Agreement”), dated as of June 24, 2020, is entered into by and among La Jolla Pharmaceutical Company, a California corporation (“Parent”), TTP Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the stockholder of Tetraphase Pharmaceuticals, Inc. set forth on Schedule A hereto (the “Stockholder”). Capitalized terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the Merger Agreement (as defined below).

LA JOLLA PHARMACEUTICAL COMPANY
La Jolla Pharmaceutical Co • March 13th, 2006 • Biological products, (no disgnostic substances)
LICENSE AGREEMENT BY AND BETWEEN
License Agreement • March 8th, 2021 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • New York

THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of February 20, 2018 (“Effective Date”) between Tetraphase Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware with a principal place of business at 480 Arsenal Street, Suite 110, Watertown, MA 02472 (“Tetraphase”), and Everest Medicines Limited, an exempted company organized and existing under the laws of Cayman Islands, with a principal place of business at Suite 4508, 45F, Tower 2, Plaza 66, 1266 Nanjing Xi Lu, Shanghai 200040, China (“Licensee”).

LA JOLLA PHARMACEUTICAL COMPANY Restricted Stock Unit Grant Agreement
Restricted Stock Unit Grant Agreement • November 13th, 2012 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • California

This Restricted Stock Unit Grant Agreement (the “Agreement”) is dated as of August 17, 2012 and is entered into between La Jolla Pharmaceutical Company, a California corporation (the “Company”), and Chester S. Zygmont, III (the “Awardee”). This award is granted outside of the Company’s 2010 Equity Incentive Plan (the “Plan”) but is governed in all respects by the terms of the Plan. Capitalized terms not otherwise defined herein shall have the respective meanings set forth in the Plan.

CONTINGENT VALUE RIGHTS AGREEMENT
Contingent Value Rights Agreement • July 29th, 2020 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • Delaware

WHEREAS, Parent, TTP Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and Tetraphase Pharmaceuticals, Inc., a Delaware corporation (including in its capacity as the surviving corporation in the Merger, the “Company”), have entered into an Agreement and Plan of Merger dated as of June 24, 2020 (as it may be amended or supplemented from time to time pursuant to the terms thereof, the “Merger Agreement”);

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!